Role of VASP Phosphorylation Assay in Monitoring the Antiplatelet Therapy

Acta Medica Martiniana

Mokan M.¹  Kovar F.¹  Fedor Marian²  Fedorova J.³  Skornova I.⁴  Samos M.⁴  Stasko J.⁴  Kubisz P.⁴  Simonova R.⁴  Duraj L.⁴ 

[1] 1st Clinic of Internal Medicine, Jessenius Faculty of Medicine and University Hospital, Martin, Slovak Republic;Clinic of Haematology and Transfusiology, JFM CU, University Hospital, Kollarova Str. N. 2, 036 01 Martin, Slovak Republic;Hemo-Medika s.r.o.. Center of Haemostasis and Thrombosis, Martin;National Center of Thrombosis and Haemostasis, Clinic of Haematology and Transfusiology, Jessenius Faculty of Medicine and University Hospital, Martin, Slovak Republic;

关键词: acute coronary syndrome;    clopidogrel;    flow cytometry;    platelet reactivity;    vasodilator stimulated phosphoprotein (vasp);   

DOI  :  10.2478/acm-2013-0008

来源: DOAJ

【 摘 要 】

Dual antiplatelet treatment with clopidogrel and aspirin represents standard regimen in prevention of thromboembolic events in patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI). One of the greatest pitfalls of clopidogrel treatment is large inter-individual variability in response. Large amount of patients does not respond adequately and therefore are not „protected“ even in spite of receiving the therapy. Poor responders are exposed to three-fold increased risk of myocardial infarction, stent thrombosis and cardiac death.

【 授权许可】

Unknown